ATI RN
ATI Pharmacology Proctored Exam
1. A healthcare professional is preparing to administer Belimumab for a client with Systemic Lupus Erythematosus. Which of the following actions should the healthcare professional plan to take?
- A. Warm the medication to room temperature before administering.
- B. Administer the medication by slow IV infusion over the recommended time frame.
- C. Dilute the medication in an appropriate solution as per manufacturer guidelines.
- D. Monitor the client for hypersensitivity reactions.
Correct answer: D
Rationale: The correct action the healthcare professional should plan to take when administering Belimumab is to monitor the client for hypersensitivity reactions. Belimumab is known to cause severe infusion reactions, including anaphylaxis in some cases. Monitoring for hypersensitivity reactions is crucial to detect and manage any adverse reactions promptly. Options A, B, and C are incorrect because warming the medication, administering by slow IV infusion, and dilution are not specific actions needed for Belimumab administration. The priority is to monitor the client for potential hypersensitivity reactions to ensure their safety.
2. A client is receiving treatment with methotrexate. Which of the following supplements should the nurse instruct the client to take?
- A. Folic acid
- B. Vitamin D
- C. Calcium
- D. Iron
Correct answer: A
Rationale: The nurse should instruct the client to take folic acid when receiving treatment with methotrexate to reduce the risk of methotrexate toxicity. Methotrexate acts as a folic acid antagonist, leading to folic acid deficiency, which can be counteracted by supplementing with folic acid. Vitamin D, calcium, and iron are not specifically recommended to counteract methotrexate effects and do not play a significant role in mitigating methotrexate toxicity.
3. A client with chronic myeloid leukemia is receiving hydroxyurea. Which of the following findings should the nurse monitor?
- A. Hyperkalemia
- B. Hypertension
- C. Neutropenia
- D. Tinnitus
Correct answer: C
Rationale: The nurse should monitor the client for neutropenia when receiving hydroxyurea, as it is a common adverse effect caused by bone marrow suppression. Neutropenia increases the risk of infections, making it crucial for the nurse to closely monitor the client's white blood cell count.
4. When starting therapy with doxorubicin, which of the following findings should the nurse instruct the client to report?
- A. Hair loss
- B. Fatigue
- C. Sore throat
- D. Red urine
Correct answer: C
Rationale: The nurse should instruct the client to report a sore throat because it can indicate an infection due to the immunosuppressive effects of doxorubicin. Doxorubicin is known to suppress the immune system, making patients more susceptible to infections. Monitoring and reporting early signs of infection, such as a sore throat, are essential to prevent complications. Hair loss and fatigue are common side effects of doxorubicin but do not typically indicate immediate concerns for infection. Red urine is a known side effect of doxorubicin but is not a priority over potentially serious infections that can arise.
5. A client is prescribed Digoxin. Which of the following findings should the nurse monitor as a sign of potential toxicity?
- A. Bradycardia
- B. Hypertension
- C. Hyperglycemia
- D. Hypocalcemia
Correct answer: A
Rationale: Bradycardia is a common sign of Digoxin toxicity. Digoxin can lead to toxicity, which can manifest as various signs and symptoms, including bradycardia. Monitoring the client's heart rate closely is crucial to detect and manage potential toxicity early. Hypertension, hyperglycemia, and hypocalcemia are not typically associated with Digoxin toxicity; therefore, they are incorrect choices.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access